LUND, SE / ACCESS Newswire / April 29, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...

LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class i ...

Soligenix recently announced an exciting update for its novel skin cancer treatment. The company reports that its flagship ...

The EMA has recommended extensions to the marketing authorizations for Adcetris, used to treat Hodgkin lymphoma, and ...

As part of its ongoing 'Your Health, Our Priority' campaign, Hamad Medical Corporation (HMC) highlighted the exceptional ...

Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”) for HyBryte(TM), a novel pho ...

CEO Leonard Mazur to present on Thursday, June 5, 2025, at 3:10 pm ET CRANFORD, N.J., May 5, 2025 /PRNewswire/ -- Citius Pharmaceuticals, I ...

Citius Oncology, Inc.’s CTOR share price has dipped by 6.04%, which has investors questioning if this is right time to buy.

treatment for up to 54 weeks in patients with early-stage cutaneous T-cell lymphoma (CTCL). Following 18 weeks of treatment, 75% of patients ac AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- via ...

Dr. Neha Mehta-Shah shares how patients can better understand their subtype of rare lymphoma, as well as expands on the ...